In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nightstar Therapeutics PLC

Division of Biogen Inc.
www.nightstarx.co.uk

Latest From Nightstar Therapeutics PLC

Roche/Spark Acquisition: First Gene Therapy Deal Clears FTC With No Divestiture

FTC found Roche would not have incentive to delay or discontinue development of Spark's gene therapy for hemophilia A. Outcome shows deals can survive closer FTC scrutiny.

M & A Gene Therapy

Gene Therapy Manufacturers Are Highly Sought Acquisition Targets

Given the transformative nature of regenerative medicines, treatments yielding greatly improved patient responses that now exist as viable products on the market, cell and gene drug developers over the past several years have been drawing deal attention. Not only through collaborative partnerships, but also as acquisition targets.

BioPharmaceutical Market Intelligence

Woodford Debacle Is A Test Of UK Biotech’s Resilience

As once-star investment funds fail, another major investor argues this is opportunity for UK biotech to demonstrate staying power.

 

United Kingdom Financing

European Life Science Companies Are Now Being ‘Properly Funded’

In the first half of 2019, life science companies raised $469m through series A rounds in Europe – a solid start to the year compared with the $686m companies raised in 2018 overall. Experts says this "rude health" should continue for the next two to three years, at least.

Europe Financing
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Ophthalmic
  • Alias(es)
  • Nightstar Therapeutics Ltd.
  • NightstaRx Ltd.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Biogen Inc.
  • Senior Management
  • David Fellows, CEO
    Senthil Sundaram, CFO
    Gregory Robinson, PhD, CSO
    Tuyen Ong, MD, Chief Dev. Officer
  • Contact Info
  • Nightstar Therapeutics PLC
    Phone: (0)20 7611 2077
    9-10 Midford Pl.
    London, W1T 5BJ
    UK
UsernamePublicRestriction

Register